Skip to main content

Research Repository

Advanced Search

All Outputs (5)

Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study (2024)
Journal Article

Objective To investigate (1) the UK-wide inactivated influenza vaccine (IIV) uptake in adults with inflammatory bowel disease (IBD), (2) the association between vaccination against influenza and IBD flare and (3) the effectiveness of IIV in preventin... Read More about Uptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study.

Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study (2024)
Journal Article

Objective The uptake and safety of pneumococcal vaccination in people with immune mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK wide pneumococcal vaccine uptake in adults with IMIDs and explored the association b... Read More about Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study.

The effectiveness of pneumococcal vaccination in adults with common immune mediated inflammatory diseases: a UK wide study using data from the Clinical Practice Research Datalink Gold (2024)
Journal Article

Background The effectiveness of pneumococcal vaccination in people with common immune mediated inflammatory diseases (IMIDs) has not been evaluated. We investigated the effectiveness of pneumococcal vaccination in preventing respiratory morbidity a... Read More about The effectiveness of pneumococcal vaccination in adults with common immune mediated inflammatory diseases: a UK wide study using data from the Clinical Practice Research Datalink Gold.

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients (2024)
Journal Article

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n=253) or Usual Care (n... Read More about Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.